ArticleCurrent oncology (Toronto, Ont.)2025
Deep Learning-Based 30-Day Mortality Prediction in Critically Ill Bone and Bone Marrow Metastasis Patients: A Multicenter Retrospective Cohort Study.
Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bone and bone marrow Metastasis (BBM) are life-threatening complications of advanced malignancies, frequently requiring intensive care and associated with high short-term mortality. However, prognostic tools specifically tailored to critically ill BBM patients are limited. This multicenter cohort study aimed to develop and validate deep learning models for predicting 30-day mortality using ICU data from MIMIC-IV, eICU-CRD, and the First Affiliated Hospital of Xinjiang Medical University. After univariate screening, XGBoost-Boruta and Lasso regression identified 11 key clinical features within 24 h of ICU admission. Thirteen deep learning models were trained using five-fold cross-validation, and their performance was evaluated through AUC, average precision, calibration, and decision curves. TabNet achieved the best internal performance (AUC 0.878; AP 0.940) and maintained strong discrimination in both same-region (eICU: AUC 0.840; AP 0.932) and cross-regional (Xinjiang: AUC 0.831; Accuracy 80.5%) validation. SHAP and attention-based interpretability analyses consistently identified SOFA, serum calcium, and albumin as dominant predictors. A TabNet-based online calculator was subsequently deployed to enable bedside mortality risk estimation. In conclusion, TabNet demonstrates potential as an accurate and interpretable tool for early mortality risk stratification in critically ill BBM patients, offering support for more timely and individualized decision-making in BBM-related critical care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.